IDEXX Q4 revenue $902M (+9%); FY24 guides $3.93-4.04B, EPS $10.84-11.33

IDEXX LABORATORIES INC /DE

2023-FY EPS reported $10.06 revenue$3,660,953,000

Q4 revenue $902M, up 9% reported and 8% organic; CAG Diagnostics recurring revenue +11% reported and +10% organic.
Q4 EPS $2.32, up 13% reported and 17% on a comparable basis; full-year EPS $10.06 (+25% reported).
FY24 revenue guidance $3.93B-$4.04B (+7.5%-10.5% reported); EPS $10.84-$11.33 (+8%-13% comparable).
Full-year operating margin expanded 330 bps reported; FY24 operating margin target 30.2%-30.7%.
New IDEXX inVue Dx slide-free cellular analyzer launch targeted for late 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

IDEXX LABORATORIES INC /DE updated its the quarter and year ended December 31, 2023 guidance (initiated).

Period: the quarter and year ended December 31, 2023
Guidance: initiated
Result: reported results

Exact text from the filing

IDEXX Laboratories, Inc. (the “Company”) announced its financial results for the quarter and year ended December 31, 2023.

View on SEC.gov

3 earnings releases filed in the last 30 days. Browse all earnings releases →

IDEXX LABORATORIES INC /DE filing history →

Source: SEC EDGAR

accession 0001157523-24-000165

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.